CMP as on 01-Jul-22 16:00₹ 80.70
Turnover (lac)₹ 8
Prev. Close₹ 81.45
Day's Vol (shares)₹ 9,550
Day's Range (₹)
CMP as on01-Jul-22 16:01₹ 80.80
Turnover (lac)₹ 2
Prev. Close₹ 81.70
Day's Vol (shares)₹ 2,655
PAT for the financial year ended March 31, 2022, was reported at Rs67.90 crore as compared to Rs61 crore in the previous financial year
As a result of this remote assessment, USFDA does not plan to take or recommend regulatory or enforcement action at this time.
The Company has received a non-exclusive license through the Medicines Patent Pool (MPP) to manufacture Molnupiravir.
The rating on the long-term bank facilities improved to "CARE A; Stable from CARE A-; Stable.
Revenue grew by 44.4% yoy. Highest ever EBITDA margin at 27.3%, driven by better product mix and realisations, the company said.
The transfer by company promoter TVVSN Murthy of 6,61,180 equity shares to Potluri Infra Projects will take place, by way of inter-se t
Promoter Group of the company Potluri Infra Projects has pledged total 8 lakh shares on December 7.
The stake increases from 0.27% to 0.77% on Aug. 17. Ramesh Babu also sells 0.50% shares in SMS Pharma to Potluri Labs.
Other than marginal delays in receipt of the payments from the customers, the company has not faced any major cash flow issues during t
The inspection was conducted by the USFDA at its API facility Kandivalasa, Andhra Pradesh, during January 13-17, the company said.
Per Order for ETF & Mutual Funds Brokerage
Per Order for Delivery, Intraday, F&O, Currency & Commodity